Luxbright AB (publ) (LXB.ST)
SEK 0.82
(-3.55%)
SEK 0.82
(-3.55%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -23.86 Million SEK | -16.35% |
| 2022 | -20.46 Million SEK | -18.54% |
| 2021 | -17.63 Million SEK | -44.8% |
| 2020 | -12.17 Million SEK | -15.8% |
| 2019 | -10.51 Million SEK | 12.82% |
| 2018 | -12.06 Million SEK | -1.53% |
| 2017 | -7.17 Million SEK | -113.39% |
| 2016 | -2.84 Million SEK | -198.12% |
| 2015 | -1.51 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -4.16 Million SEK | 64.95% |
| 2024 Q2 | -4.16 Million SEK | 0.0% |
| 2023 Q2 | -11.78 Million SEK | -99.76% |
| 2023 Q4 | -12.53 Million SEK | -102.11% |
| 2023 FY | - SEK | -16.35% |
| 2023 Q3 | -6.2 Million SEK | 47.35% |
| 2023 Q1 | -5.89 Million SEK | 43.29% |
| 2022 Q2 | -10.95 Million SEK | -112.45% |
| 2022 Q4 | -10.4 Million SEK | -103.62% |
| 2022 Q3 | -5.1 Million SEK | 53.38% |
| 2022 Q1 | -5.15 Million SEK | -15.19% |
| 2022 FY | - SEK | -18.54% |
| 2021 Q1 | -4.33 Million SEK | 45.01% |
| 2021 Q2 | -9.37 Million SEK | -116.13% |
| 2021 Q3 | -4.47 Million SEK | 52.26% |
| 2021 Q4 | -4.47 Million SEK | 0.0% |
| 2021 FY | - SEK | -44.8% |
| 2020 Q4 | -7.89 Million SEK | -120.14% |
| 2020 Q2 | -5.03 Million SEK | -100.93% |
| 2020 Q3 | -3.58 Million SEK | 28.77% |
| 2020 FY | - SEK | -15.8% |
| 2020 Q1 | -2.5 Million SEK | 60.79% |
| 2019 Q3 | -3.04 Million SEK | 50.22% |
| 2019 FY | - SEK | 12.82% |
| 2019 Q4 | -6.38 Million SEK | -109.71% |
| 2019 Q2 | -6.11 Million SEK | -176.66% |
| 2019 Q1 | -2.21 Million SEK | 0.0% |
| 2018 FY | - SEK | -1.53% |
| 2017 FY | - SEK | -113.39% |
| 2016 FY | - SEK | -198.12% |
| 2015 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 69.053% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 105.794% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 105.794% |
| Arcoma AB | 6.24 Million SEK | 481.99% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 73.476% |
| BICO Group AB (publ) | 322.3 Million SEK | 107.405% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 136.173% |
| CellaVision AB (publ) | 207.24 Million SEK | 111.516% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 65.11% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 14.588% |
| C-Rad AB (publ) | 48.9 Million SEK | 148.803% |
| Duearity AB (publ) | -24.77 Million SEK | 3.682% |
| Dignitana AB (publ) | -264 Thousand SEK | -8940.43% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 72.786% |
| Getinge AB (publ) | 5.92 Billion SEK | 100.403% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 64.51% |
| Iconovo AB (publ) | -35.33 Million SEK | 32.457% |
| Integrum AB (publ) | 8.76 Million SEK | 372.404% |
| Mentice AB (publ) | 28.87 Million SEK | 182.661% |
| OssDsign AB (publ) | -122.02 Million SEK | 80.44% |
| Paxman AB (publ) | 31.22 Million SEK | 176.425% |
| Promimic AB (publ) | -3.68 Million SEK | -547.849% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 84.142% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 53.951% |
| ScandiDos AB (publ) | -13.35 Million SEK | -78.697% |
| Sectra AB (publ) | 615.06 Million SEK | 103.88% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 53.813% |
| Senzime AB (publ) | -118.82 Million SEK | 79.914% |
| SpectraCure AB (publ) | -20.96 Million SEK | -13.819% |
| Stille AB | 56.04 Million SEK | 142.588% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 99.251% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 118.856% |